Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalMarket CapitalizationReturn on AssetsReturn on Capital EmployedReturn on Equity

Denali Therapeutics (DNLI) Operating Margin: 2018-2023

Historic Operating Margin for Denali Therapeutics (DNLI) over the last 6 years, with Sep 2023 value amounting to -8,981.45%.

  • Denali Therapeutics' Operating Margin fell 596133.00% to -8,981.45% in Q3 2023 from the same period last year, while for Sep 2023 it was -49.73%, marking a year-over-year increase of 23260.00%. This contributed to the annual value of -59.51% for FY2023, which is 25465.00% up from last year.
  • Latest data reveals that Denali Therapeutics reported Operating Margin of -8,981.45% as of Q3 2023, which was down 15,595.10% from 57.96% recorded in Q2 2023.
  • In the past 5 years, Denali Therapeutics' Operating Margin ranged from a high of 77.04% in Q4 2020 and a low of -8,981.45% during Q3 2023.
  • Its 3-year average for Operating Margin is -1,557.59%, with a median of -616.28% in 2021.
  • Per our database at Business Quant, Denali Therapeutics' Operating Margin soared by 300,596bps in 2019 and then tumbled by 596,133bps in 2023.
  • Denali Therapeutics' Operating Margin (Quarterly) stood at -1,236.26% in 2019, then spiked by 131,330bps to 77.04% in 2020, then tumbled by 69,332bps to -616.28% in 2021, then crashed by 40,817bps to -1,024.45% in 2022, then tumbled by 596,133bps to -8,981.45% in 2023.
  • Its last three reported values are -8,981.45% in Q3 2023, 57.96% for Q2 2023, and -343.80% during Q1 2023.